Parkin Rebecca A, Murray Andrew J
Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.
Front Reprod Health. 2024 Jul 8;6:1355922. doi: 10.3389/frph.2024.1355922. eCollection 2024.
Oestradiol withdrawal at menopause predisposes women to metabolic syndrome, a cluster of interrelated conditions including obesity, insulin resistance, dyslipidaemia and hypertension that together confer an increased risk of developing type 2 diabetes mellitus and cardiovascular disease. Hormone replacement therapies are commonly used to treat acute symptoms of the perimenopausal period, and whilst they have been associated with metabolic improvements in many studies, long-term use is considered unviable. Novel approaches are required to mitigate the risk of postmenopausal metabolic syndrome. In 2012, the exercise-inducible myokine irisin was isolated from the skeletal muscle of mice and identified to have anti-obesity and antidiabetic effects . Irisin is now recognised to exert pleiotropic action on cognitive, bone and metabolic health. There is accumulating evidence from and rodent studies that irisin can mitigate each component condition of metabolic syndrome. In postmenopausal women, independent associations have been observed between (a) exercise and plasma irisin concentration and (b) plasma irisin concentration and reduced incidence of metabolic syndrome. To date, however, no study has considered the mechanistic basis by which irisin, whether exercise-induced or exogenously administered, could reduce the incidence or severity of metabolic syndrome in postmenopausal women. This review aims to analyse the literature concerning the metabolic actions of irisin, with a focus on its therapeutic potential for metabolic syndrome driven by a state of oestradiol depletion. It evaluates the practicality of exercise as a therapy and discusses other irisin-based therapeutic strategies that may alleviate postmenopausal metabolic syndrome. Finally, it highlights areas where future research is required to advance knowledge of irisin's biological action such that it could be considered a viable candidate for clinical application.
绝经时雌二醇水平下降使女性易患代谢综合征,这是一组相互关联的病症,包括肥胖、胰岛素抵抗、血脂异常和高血压,这些因素共同增加了患2型糖尿病和心血管疾病的风险。激素替代疗法常用于治疗围绝经期的急性症状,虽然在许多研究中它与代谢改善有关,但长期使用被认为不可行。需要新的方法来降低绝经后代谢综合征的风险。2012年,运动诱导的肌动蛋白鸢尾素从小鼠骨骼肌中分离出来,并被确定具有抗肥胖和抗糖尿病作用。鸢尾素现在被认为对认知、骨骼和代谢健康具有多效性作用。越来越多的人体和啮齿动物研究证据表明,鸢尾素可以减轻代谢综合征的各个组成病症。在绝经后女性中,已经观察到(a)运动与血浆鸢尾素浓度之间以及(b)血浆鸢尾素浓度与代谢综合征发病率降低之间存在独立关联。然而,迄今为止,尚无研究探讨鸢尾素(无论是运动诱导的还是外源性给予的)能够降低绝经后女性代谢综合征发病率或严重程度的机制基础。本综述旨在分析有关鸢尾素代谢作用的文献,重点关注其对由雌二醇缺乏状态驱动的代谢综合征的治疗潜力。它评估了运动作为一种治疗方法的实用性,并讨论了其他基于鸢尾素的治疗策略,这些策略可能减轻绝经后代谢综合征。最后,它强调了未来研究需要推进对鸢尾素生物学作用的认识的领域,以便将其视为临床应用的可行候选物。